New York-based Bristol-Myers Squibb (NYSE: BMY) will collaborate with Clovis Oncology (Nasdaq: CLVS) to test a new combination therapy, Opdivo (nivolumab) plus Rubraca (rucaparib).
The companies plan to launch Phase III trials in the USA and Europe this year, exploring the combination as a first-line maintenance therapy in ovarian and breast cancer, as well as a Phase II trial in prostate cancer.
Rubraca is a small molecule which inhibits PARP, a particular enzyme, indicated in the USA for use against ovarian cancer. In March, the company presented data on a trial investigating the drug in this therapeutic area.
This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.
Login to your accountTry before you buy
7 day trial access
Become a subscriber
Or £77 per month
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed
Chairman, Sanofi Aventis UK
Copyright © The Pharma Letter 2024 | Headless Content Management with Blaze